Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
Date:1/23/2013

NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of MAP Pharmaceuticals, Inc. ("MAP Pharmaceuticals" or the "Company") (NASDAQ: MAPP) (ISIN: US56509R1086) (CUSIP: 56509R108) concerning the proposed acquisition of MAP Pharmaceuticals by Allergan, Inc. in a transaction valued at approximately $985 million in cash.

The investigation concerns whether the MAP Pharmaceuticals directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value.  Under the terms of the agreement, MAP Pharmaceuticals shareholders will be entitled to receive $25.00 per share in cash for each share of MAP Pharmaceuticals common stock.  However, at least one analyst noted that the offered price undervalues MAP Pharmaceuticals' new migraine treatment drug Levadex.

MAP Pharmaceuticals shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 237.

The firm is also investigating actions on behalf of shareholders for the following companies: Arbitron Inc., Net1 Ueps Technologies, Inc., Hi-Crush Partners LP, Intermec, Inc., SandRidge Energy, Inc., Abiomed, Inc., Universal Technical Institute, and Clearwire Corporation, Ameristar Casinos, Inc. K-Swiss, Inc., Neptune Technologies Bioressources, Inc. Telanetix, Inc.

The Pomerantz Firm, with offices in New York, Chicago and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.


'/>"/>
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Announces Webcast of Annual Meeting of Shareholders
2. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
3. SHAREHOLDER ALERT: Morgan & Morgan announces an investigation of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) and whether senior management and the board of directors violated fiduciary duties owed to Vertex shareholders.
4. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
5. SurgLine International, Inc. Shareholder Update
6. Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting
7. Cannabis Science Provides Corporate Guidance on Preclinical Initiatives and Recent Corporate Developments for its Shareholders; CBIS Announces plans for 1st Q of 2013 Webinar Investor Call
8. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
9. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
10. Medbox Announces Increase in Shareholder Base and Record Revenue Generated in Q3
11. Cardinal Health Announces Preliminary Shareholder Voting Results at 2012 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , Mar. 29, 2017 Research and ... Systems Market 2014 - 2025" report to their offering. ... ... USD 303.7 million by 2025. Increasing geriatric population prone to ... for orthopedic navigation systems over the forecast period. Osteoarthritis and ...
(Date:3/29/2017)... March 29, 2017  The Global Health Innovative ... partnership formed to battle infectious diseases around the ... million* that could help deliver a range of ... conditions. This latest round of ... clinical trial testing a pediatric formulation of a ...
(Date:3/29/2017)... BEACH, Calif. , March 29, 2017 /PRNewswire/ ... have recognized remote monitoring devices like  Soberlink Systems ...   The consensus paper, published in early 2017, ... practical and valuable in managing patient recovery." ... in the Journal of Addiction Medicine, detail a ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in 2009 ... have participated in the program every summer. The 2017 Serve, Learn, & Empower ... Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my daughter ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis ... Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved ... states. Ingredients in HeartBoost, an over the counter heart healthy drink, can reduce ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Dr. Angela ... early orthodontic treatment and accepting new pediatric patients, with or without a referral. Dr. ... patients have a better orthodontic outcome and experience. When patients receive early treatment, they ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium ... finalization of the company’s executive management team with prominent executives from both inside and ... Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty years ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):